secwatch.observer — SEC 8-K summary
======================================

Issuer:     Design Therapeutics, Inc. (DSGN)
CIK:        0001807120
Form:       8-K
Filed at:   2025-08-07T23:59:59+00:00
Accession:  0000950170-25-105008
Event type: earnings
Sentiment:  neutral
Materiality: 0.70
Item codes: 2.02, 7.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Design Therapeutics Q2 net loss $19.1M; FDA clinical hold on DT-216P2 US IND; cash $216.3M
--------------------------------------------------------------------------------

- Net loss of $19.1M for Q2 2025; R&D expense $15.7M, G&A $5.8M; cash and securities $216.3M as of June 30, 2025.
- Early human PK data for DT-216P2 shows favorable translation from NHPs; improved AUC and sustained plasma levels vs DT-216P1.
- FDA placed clinical hold on DT-216P2 US IND over starting dose; company plans to address with clinical/nonclinical data; RESTORE-FA trial continues outside US.
- Phase 2 biomarker trial of DT-168 in Fuchs Endothelial Corneal Dystrophy patients has been initiated.
- Preclinical DM1 program on track for development candidate selection in H2 2025; Huntington's disease preclinical characterization ongoing.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1807120/000095017025105008/0000950170-25-105008-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1807120/000095017025105008/dsgn-20250807.htm
  HTML page:      https://secwatch.observer/filing/0000950170-25-105008

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer